Lux Capital

Mendaera is a medtech startup dedicated to advancing healthcare technologies, particularly through the development of surgical robots and diagnostic tools. The company aims to digitize clinical judgment and technical expertise, ensuring that high-quality care is accessible to all patients in various care settings. Mendaera's platform, currently under development, integrates robotics, artificial intelligence, real-time imaging, and connectivity to facilitate precise and consistent point-of-care interventions. By aiding physicians in image acquisition and interpretation, Mendaera seeks to eliminate barriers in the patient journey, accelerate recovery, and reduce healthcare costs, thereby enhancing the capabilities of healthcare professionals in performing medical procedures effectively.

Vesta Healthcare is a technology and clinical services organization that focuses on enhancing the connection between caregivers and the broader care team. The company provides 24/7 telehealth support for caregivers and care recipients, particularly targeting high-need, frail senior populations. By partnering with home care agencies, health plans, and healthcare providers, Vesta Healthcare develops value-based population health programs that prioritize clinical quality, improved health outcomes, and personalized engagement. Originally established as Hometeam Technologies, Inc. in 2008, the company rebranded to Vesta Healthcare in January 2020 and is headquartered in New York, New York.

Inductive Bio specializes in providing a machine learning platform that enhances the compound optimization process for drug development. The company focuses on addressing ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) challenges by building comprehensive datasets and machine learning models. This enables scientists to efficiently identify and refine small molecule compounds, transforming initial candidates into viable leads more rapidly and with improved properties. By streamlining the optimization process, Inductive Bio supports the development of new therapeutics, ultimately contributing to advancements in the pharmaceutical industry.

Cromatic develops software aimed at simplifying the outsourcing of research and development for life sciences companies. By providing a platform that facilitates the identification and management of scientific outsourcing partners, Cromatic allows health-tech companies to connect with contract research organizations more efficiently. This innovation enables scientists to launch and scale their ventures without the need for a physical laboratory, allowing them to concentrate on their research and development efforts. Ultimately, Cromatic enhances the efficiency of R&D processes, empowering scientist entrepreneurs to focus on advancing scientific discovery.

Mendaera is a medtech startup dedicated to advancing healthcare technologies, particularly through the development of surgical robots and diagnostic tools. The company aims to digitize clinical judgment and technical expertise, ensuring that high-quality care is accessible to all patients in various care settings. Mendaera's platform, currently under development, integrates robotics, artificial intelligence, real-time imaging, and connectivity to facilitate precise and consistent point-of-care interventions. By aiding physicians in image acquisition and interpretation, Mendaera seeks to eliminate barriers in the patient journey, accelerate recovery, and reduce healthcare costs, thereby enhancing the capabilities of healthcare professionals in performing medical procedures effectively.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Osmo is a company that combines artificial intelligence with olfactory science to create a platform that gives computers a sense of smell. Initially focused on the fragrance industry, Osmo develops aroma molecules for products such as perfumes, shampoos, lotions, and candles. In addition to enhancing consumer experiences, the technology has the potential to detect diseases earlier and track pandemics, ultimately aiming to improve overall health and well-being. By addressing these challenges, Osmo seeks to revolutionize how scent is integrated into everyday life and its implications for human health.

WellTheory is a virtual care platform focused on providing services for individuals with autoimmune and inflammatory conditions. It aims to support clients throughout their immunological journey by integrating community care, dietary and lifestyle modifications, personalized insights, and evidence-based recommendations into a cohesive membership experience. This approach is designed to equip individuals with the necessary tools and knowledge for effective treatment and management of their conditions.

H1 is a New York-based healthcare platform founded in 2017 that serves as a connector for life sciences companies, hospitals, academic medical centers, and health systems. Its platform specializes in providing real-time data and analytics to facilitate informed decision-making throughout the therapeutic development process, from fundraising to product launch. By offering insights on healthcare professionals, clinical research, and industry experts, H1 enables organizations to benchmark their performance and access critical information that accelerates the discovery and development of therapies aimed at combating diseases. The company positions itself as a trusted source within the healthcare ecosystem, leveraging data to enhance collaboration and innovation across the industry.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

AllStripes is a healthcare technology company focused on accelerating the development of treatments for rare diseases. The company has created a platform that produces regulatory-ready evidence to support rare disease research and drug development. This platform operates as a two-sided network where patients with rare diseases and advocacy groups contribute valuable information, while life science companies utilize this data to identify new drug candidates. Additionally, AllStripes offers a patient application that allows individuals to engage in treatment research online and leverage their own medical data, fostering a collaborative environment aimed at advancing medical research for rare conditions.

Carbon Health is a tech-enabled healthcare company founded in 2015 and headquartered in San Francisco, California. It offers a comprehensive virtual care experience, providing primary care services through a mobile application that allows users to manage treatment plans, prescriptions, and lab reports all in one place. The company focuses on delivering accessible healthcare through various channels, including clinics, pop-up sites, video consultations, and its mobile app. Carbon Health also developed a coronavirus assessment tool and implemented COVID-19 testing in California, demonstrating its commitment to adapting healthcare services to meet urgent public health needs.

Vesta Healthcare is a technology and clinical services organization that focuses on enhancing the connection between caregivers and the broader care team. The company provides 24/7 telehealth support for caregivers and care recipients, particularly targeting high-need, frail senior populations. By partnering with home care agencies, health plans, and healthcare providers, Vesta Healthcare develops value-based population health programs that prioritize clinical quality, improved health outcomes, and personalized engagement. Originally established as Hometeam Technologies, Inc. in 2008, the company rebranded to Vesta Healthcare in January 2020 and is headquartered in New York, New York.

H1 is a New York-based healthcare platform founded in 2017 that serves as a connector for life sciences companies, hospitals, academic medical centers, and health systems. Its platform specializes in providing real-time data and analytics to facilitate informed decision-making throughout the therapeutic development process, from fundraising to product launch. By offering insights on healthcare professionals, clinical research, and industry experts, H1 enables organizations to benchmark their performance and access critical information that accelerates the discovery and development of therapies aimed at combating diseases. The company positions itself as a trusted source within the healthcare ecosystem, leveraging data to enhance collaboration and innovation across the industry.

EverlyWell develops do-it-yourself kits for a vast range of at-home regulatory-compliant diagnostic tests including food sensitivity, fertility, hormones, STDs, thyroid, and metabolism among the others, allowing users to perform tests at home and receive physician-reviewed results and insights on their mobile devices. EverlyWell also provides at-home covid testing.

Thrive Earlier Detection Corp. is a healthcare company that specializes in developing advanced blood testing technologies for early cancer detection. Its flagship product, CancerSEEK, is a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma, allowing for the identification of various cancers at their nascent stages, often before symptoms manifest. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate cancer screening into standard medical practice. The company leverages real-world data and machine learning to enhance the accuracy of cancer detection, facilitate follow-up testing, and streamline the transition to oncological care. Thrive operates as a subsidiary of Exact Sciences Corporation and has received investments from notable firms including Third Rock Ventures and Section 32.

AllStripes is a healthcare technology company focused on accelerating the development of treatments for rare diseases. The company has created a platform that produces regulatory-ready evidence to support rare disease research and drug development. This platform operates as a two-sided network where patients with rare diseases and advocacy groups contribute valuable information, while life science companies utilize this data to identify new drug candidates. Additionally, AllStripes offers a patient application that allows individuals to engage in treatment research online and leverage their own medical data, fostering a collaborative environment aimed at advancing medical research for rare conditions.

Avail Medsystems, Inc. is a digital healthcare company that develops a platform designed to remotely connect healthcare experts with practitioners. The company's integrated audio/visual hardware and software system facilitates procedural support, observation, and clinical education services, allowing healthcare professionals to collaborate effectively. By enabling real-time access to clinical expertise, Avail aims to eliminate physical, economic, and logistical barriers in the healthcare industry. This approach promotes innovation and enhances the adoption of medical tools and techniques, ultimately improving patient care. Founded in 2017 and based in Palo Alto, California, Avail Medsystems was previously known as Nurep, Inc. and underwent a name change in March 2018.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Vesta Healthcare is a technology and clinical services organization that focuses on enhancing the connection between caregivers and the broader care team. The company provides 24/7 telehealth support for caregivers and care recipients, particularly targeting high-need, frail senior populations. By partnering with home care agencies, health plans, and healthcare providers, Vesta Healthcare develops value-based population health programs that prioritize clinical quality, improved health outcomes, and personalized engagement. Originally established as Hometeam Technologies, Inc. in 2008, the company rebranded to Vesta Healthcare in January 2020 and is headquartered in New York, New York.

CTRL-Labs Corporation, founded in 2015 and based in New York City, specializes in developing non-invasive neural interface technology aimed at enhancing the interaction between humans and machines. The company's flagship product, the CTRL-kit, is a wireless wristband equipped with sensors that captures neural signals, allowing users to control digital devices through simple electronic pulses. This innovative platform is designed to support various applications in virtual reality, augmented reality, robotics, productivity, and clinical research. By providing developers with a software development kit (SDK) and application programming interface (API), CTRL-Labs enables the integration of neural control into their applications. The company's long-term vision focuses on fostering mass consumer adoption of neural interfaces, establishing a new standard for human-machine collaboration that transforms how users engage with technology.

Vesta Healthcare is a technology and clinical services organization that focuses on enhancing the connection between caregivers and the broader care team. The company provides 24/7 telehealth support for caregivers and care recipients, particularly targeting high-need, frail senior populations. By partnering with home care agencies, health plans, and healthcare providers, Vesta Healthcare develops value-based population health programs that prioritize clinical quality, improved health outcomes, and personalized engagement. Originally established as Hometeam Technologies, Inc. in 2008, the company rebranded to Vesta Healthcare in January 2020 and is headquartered in New York, New York.

Visla Labs Inc. is a San Francisco-based startup focused on developing an artificial intelligence platform tailored for the radiology and healthcare sectors. Incorporated in 2018, the company is dedicated to advancing healthcare technology, aiming to create innovative solutions that enhance diagnostic processes and patient care. With venture capital backing, Visla Labs is positioned for significant growth as it approaches a critical milestone in its development.

AllStripes is a healthcare technology company focused on accelerating the development of treatments for rare diseases. The company has created a platform that produces regulatory-ready evidence to support rare disease research and drug development. This platform operates as a two-sided network where patients with rare diseases and advocacy groups contribute valuable information, while life science companies utilize this data to identify new drug candidates. Additionally, AllStripes offers a patient application that allows individuals to engage in treatment research online and leverage their own medical data, fostering a collaborative environment aimed at advancing medical research for rare conditions.

Vium, Inc. is a biotechnology company focused on transforming preclinical research and enhancing animal welfare through the development of digital biomarkers. Fully accredited by AAALAC International, Vium has received commendation for its commitment to the principles of humane animal research. The company's platform, known as Digital Vivarium and Vium Cloud, integrates advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively capture and analyze physiological metrics and behaviors. This innovative approach provides researchers across biotechnology, pharmaceutical, and academic sectors with accurate data that facilitates better decision-making regarding which compounds to advance to clinical trials. Founded in 2013 and headquartered in San Mateo, California, Vium aims to accelerate the preclinical drug discovery and development pipeline while ensuring ethical standards in research practices.

CTRL-Labs Corporation, founded in 2015 and based in New York City, specializes in developing non-invasive neural interface technology aimed at enhancing the interaction between humans and machines. The company's flagship product, the CTRL-kit, is a wireless wristband equipped with sensors that captures neural signals, allowing users to control digital devices through simple electronic pulses. This innovative platform is designed to support various applications in virtual reality, augmented reality, robotics, productivity, and clinical research. By providing developers with a software development kit (SDK) and application programming interface (API), CTRL-Labs enables the integration of neural control into their applications. The company's long-term vision focuses on fostering mass consumer adoption of neural interfaces, establishing a new standard for human-machine collaboration that transforms how users engage with technology.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Physera, Inc. is a company focused on delivering digital musculoskeletal care by connecting patients with physical therapists through a mobile application. Founded in 2015 and based in Palo Alto, California, the platform provides patients suffering from musculoskeletal injuries with access to tailored workout plans, along with features such as in-app animations and voice prompts designed to facilitate exercise therapy and alleviate pain. The application collects data to help assess the effectiveness of these routines, enabling physical therapists to create targeted recovery and maintenance plans that can be coordinated remotely. Physera serves a diverse clientele, including patients with muscular pain, self-insured employers, and large health plans. As of May 2020, Physera operates as a subsidiary of Omada Health, Inc.

3Scan, Inc. specializes in developing advanced microscopy tools and software for automated tissue sectioning and imaging, primarily aimed at enhancing large-scale sample analysis and 3D visualizations. Founded in 2010 and based in San Francisco, California, the company focuses on addressing diseases that manifest at the tissue level, including cancer, heart disease, and neurodegenerative disorders. By integrating automation, machine learning, and computer vision, 3Scan's technology enables researchers and medical professionals to achieve greater throughput, improved quantification, and extensive image analysis compared to traditional histopathology methods. This data-driven approach aims to deepen the understanding of tissue biology, facilitating the discovery of new diagnostics and therapeutics. 3Scan was acquired by Transcriptic, Inc. in 2019.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Vium, Inc. is a biotechnology company focused on transforming preclinical research and enhancing animal welfare through the development of digital biomarkers. Fully accredited by AAALAC International, Vium has received commendation for its commitment to the principles of humane animal research. The company's platform, known as Digital Vivarium and Vium Cloud, integrates advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively capture and analyze physiological metrics and behaviors. This innovative approach provides researchers across biotechnology, pharmaceutical, and academic sectors with accurate data that facilitates better decision-making regarding which compounds to advance to clinical trials. Founded in 2013 and headquartered in San Mateo, California, Vium aims to accelerate the preclinical drug discovery and development pipeline while ensuring ethical standards in research practices.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Sols, Inc., established in 2013 and headquartered in New York, specializes in innovative foot support solutions. The company offers customized orthotics, including medical-grade 3D printed SOLSRx and consumer-friendly ExoSOLS insoles, designed to address foot alignment, promote proper gait, and relieve plantar fascia pressure. Sols' unique platform combines software, mobile applications, and advanced computer vision and machine learning technologies to create precise, personalized footwear products. The company serves customers in the United States and is a subsidiary of Aetrex Worldwide, Inc.

3Scan, Inc. specializes in developing advanced microscopy tools and software for automated tissue sectioning and imaging, primarily aimed at enhancing large-scale sample analysis and 3D visualizations. Founded in 2010 and based in San Francisco, California, the company focuses on addressing diseases that manifest at the tissue level, including cancer, heart disease, and neurodegenerative disorders. By integrating automation, machine learning, and computer vision, 3Scan's technology enables researchers and medical professionals to achieve greater throughput, improved quantification, and extensive image analysis compared to traditional histopathology methods. This data-driven approach aims to deepen the understanding of tissue biology, facilitating the discovery of new diagnostics and therapeutics. 3Scan was acquired by Transcriptic, Inc. in 2019.

Vium, Inc. is a biotechnology company focused on transforming preclinical research and enhancing animal welfare through the development of digital biomarkers. Fully accredited by AAALAC International, Vium has received commendation for its commitment to the principles of humane animal research. The company's platform, known as Digital Vivarium and Vium Cloud, integrates advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively capture and analyze physiological metrics and behaviors. This innovative approach provides researchers across biotechnology, pharmaceutical, and academic sectors with accurate data that facilitates better decision-making regarding which compounds to advance to clinical trials. Founded in 2013 and headquartered in San Mateo, California, Vium aims to accelerate the preclinical drug discovery and development pipeline while ensuring ethical standards in research practices.

Pager, Inc. operates an on-demand service platform that connects patients with healthcare services in various settings, including their homes, offices, and hotels. The company offers a mobile application that addresses urgent care needs such as infections, fevers, and allergies, while also providing services like nurse chat, teleconsultations, screening, vaccinations, and prescription delivery. Pager aims to improve healthcare access and decision-making by employing a flexible platform that serves health plans and systems, enhancing consumer experience through information, guidance, and coordination. By integrating clinical and service teams with advanced technology, Pager facilitates triage, telemedicine, appointment scheduling, and health advocacy, fostering a comprehensive care experience. The company, incorporated in 2013 and based in New York, supports over 15 million covered lives in the United States and Latin America.

Sols, Inc., established in 2013 and headquartered in New York, specializes in innovative foot support solutions. The company offers customized orthotics, including medical-grade 3D printed SOLSRx and consumer-friendly ExoSOLS insoles, designed to address foot alignment, promote proper gait, and relieve plantar fascia pressure. Sols' unique platform combines software, mobile applications, and advanced computer vision and machine learning technologies to create precise, personalized footwear products. The company serves customers in the United States and is a subsidiary of Aetrex Worldwide, Inc.

Sols, Inc., established in 2013 and headquartered in New York, specializes in innovative foot support solutions. The company offers customized orthotics, including medical-grade 3D printed SOLSRx and consumer-friendly ExoSOLS insoles, designed to address foot alignment, promote proper gait, and relieve plantar fascia pressure. Sols' unique platform combines software, mobile applications, and advanced computer vision and machine learning technologies to create precise, personalized footwear products. The company serves customers in the United States and is a subsidiary of Aetrex Worldwide, Inc.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

Inductive Bio specializes in providing a machine learning platform that enhances the compound optimization process for drug development. The company focuses on addressing ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) challenges by building comprehensive datasets and machine learning models. This enables scientists to efficiently identify and refine small molecule compounds, transforming initial candidates into viable leads more rapidly and with improved properties. By streamlining the optimization process, Inductive Bio supports the development of new therapeutics, ultimately contributing to advancements in the pharmaceutical industry.